# Alumis Inc. Common Stock (ALMS)

> Alumis Inc. Common Stock (ALMS) trades at $5.85 (-10.70%) as of 2:43:33 PM EST on Nov 5, 2026, -13.74% over the past month. Market cap is $847.8M, with 4.9 days to cover in short interest.

Canonical: https://massive.com/quote/alms
Data as of: 2026-11-05T19:43:33.256Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$5.85** -0.70 (-10.70%)
As of 2:43:33 PM EST on Nov 5, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Alumis Inc. Common Stock (ALMS) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -10.84% |
| 1W | -15.24% |
| 1M | -13.74% |
| YTD | -40.16% |
| 1Y | +23.73% |
| 52-wk range | $4.40 – $31.35 |

From daily closes through Nov 5, 2026.

## Key statistics

Today's trading snapshot for ALMS: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $5.78 – $6.53 |
| Open | $6.51 |
| Prev close | $6.55 |
| Volume | 987.33K |
| Market cap | $847.8M |
| Shares out | 129.44M |

## Valuation and profitability ratios

Valuation and profitability ratios for Alumis Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 113.72 |
| P/B | 1.86 |
| P/FCF | — |
| ROE | -97.1% |
| ROA | -78.3% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 3, 2026

## Insider trading

[Alumis Inc. Common Stock (ALMS) insider trading](https://massive.com/quote/alms/insider-trading.md): open-market Form 4 buys and sells by Alumis Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Alumis Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Sep 1, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “On September 1, 2026, Alumis Inc. issued a press release titled “Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE).” The Company is also filing slides presented by the Company at a webcast regarding the LUMUS Phase 2b topline results on September 1, 2026.”
- Aug 10, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Envudeucitinib Long-Term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies”
- Jul 2, 2026 · [New auditor engagement](https://massive.com/quote/sec-filings/8-k/auditor-changes.md)
  “The Company's stockholders ratified the appointment by the Company's Audit Committee of PricewaterhouseCoopers LLP as the Company's independent auditor for the fiscal year ending December 31, 2026. The final voting results are as follows: 105,924,017 votes for, 283,113 votes against, 242,002 abstentions.”
- Jun 29, 2026 · Investor presentation
  “On June 29, 2026, Alumis Inc. (the "Company") updated its corporate presentation for use in meetings with investors, analysts, and others. The presentation is available on the Company's website and a copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”
- Mar 30, 2026 · [Clinical trial results](https://massive.com/quote/sec-filings/8-k/clinical-trial-results.md)
  “Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis”

## ALMS short interest

How heavily ALMS is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 4.9 |
| Short interest | 11.08M |
| Avg volume | 2.28M |

As of Oct 15, 2026 · reported to FINRA twice monthly.

## ALMS news

The latest news and headlines about Alumis Inc. Common Stock (ALMS).

- [Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter](https://www.fool.com/coverage/filings/2026/05/17/alumis-stock-has-soared-400-cormorant-bought-another-usd8-million-last-quarter/?source=iedfolrf0000001) · The Motley Fool · May 17, 2026 · positive sentiment
- [The Psoriasis Clinical Trial Pipeline Boom as 90+ Companies are in the Race for Better Treatments \| DelveInsight](https://www.globenewswire.com/news-release/2026/04/14/3273777/0/en/The-Psoriasis-Clinical-Trial-Pipeline-Boom-as-90-Companies-are-in-the-Race-for-Better-Treatments-DelveInsight.html) · GlobeNewswire Inc. · Apr 14, 2026 · positive sentiment
- [Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis](https://www.globenewswire.com/news-release/2026/03/28/3264196/0/en/Alumis-Envudeucitinib-Delivers-Early-and-Robust-Improvements-in-Skin-Clearance-Quality-of-Life-and-Psoriasis-Symptoms-in-Two-Phase-3-Trials-Underscoring-Its-Potential-as-a-Leading-.html) · GlobeNewswire Inc. · Mar 28, 2026 · positive sentiment
- [Alumis Announces Pricing of Upsized Public Offering of Common Stock](https://www.globenewswire.com/news-release/2026/01/08/3215030/0/en/Alumis-Announces-Pricing-of-Upsized-Public-Offering-of-Common-Stock.html) · GlobeNewswire Inc. · Jan 7, 2026 · positive sentiment
- [Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib](https://www.fool.com/coverage/stock-market-today/2026/01/06/stock-market-today-jan-6-alumis-shares-surge-on-positive-phase-3-psoriasis-data-for-envudeucitinib/?source=iedfolrf0000001) · The Motley Fool · Jan 6, 2026 · positive sentiment

## About Alumis Inc. Common Stock

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 239 |
| Listed | Jun 28, 2024 |

[Company website](https://www.alumis.com)

## FAQ

### What is the Alumis Inc. Common Stock (ALMS) stock price today?

Alumis Inc. Common Stock (ALMS) is trading at $5.85 (-10.70% on the day) as of 2:43:33 PM EST on Nov 5, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Alumis Inc. Common Stock?

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS")…

### What is the short interest in ALMS?

As of Oct 15, 2026, ALMS has 11.08M shares short and 4.9 days to cover.

### What exchange is ALMS listed on?

Alumis Inc. Common Stock (ALMS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ALMS quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ALMS`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Alumis Inc. Common Stock (ALMS) insider trading](https://massive.com/quote/alms/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms